Related references
Note: Only part of the references are listed.Impact of FKS1 Genotype on Echinocandin In Vitro Susceptibility in Candida auris and In Vivo Response in a Murine Model of Infection
Dipti Sharma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Candida auris Candidemia in Critically Ill, Colonized Patients: Cumulative Incidence and Risk Factors
Federica Briano et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Initial Results of the International Efforts in Screening New Agents against Candida auris
Vanice Rodrigues Poester et al.
JOURNAL OF FUNGI (2022)
Fluconazole resistant Candida auris clinical isolates have increased levels of cell wall chitin and increased susceptibility to a glucosamine-6-phosphate synthase inhibitor
Garima Shahi et al.
Cell Surface (2022)
Antifungal Combinations against Candida Species: From Bench to Bedside
Simona Fioriti et al.
JOURNAL OF FUNGI (2022)
Outbreak of Candida auris infection in a COVID-19 hospital in Mexico
Hiram Villanueva-Lozano et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Antifungal activity of nikkomycin Z against Candida auris
Meghan L. Bentz et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Raman Imaging of Pathogenic Candida auris: Visualization of Structural Characteristics and Machine-Learning Identification
Giuseppe Pezzotti et al.
FRONTIERS IN MICROBIOLOGY (2021)
Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
Renato Kovacs et al.
MICROORGANISMS (2021)
Candida auris Invasive Infections during a COVID-19 Case Surge
Blake M. Hanson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
Unai Caballero et al.
PHARMACEUTICS (2021)
Hope on the Horizon: Novel Fungal Treatments in Development
Adriana M. Rauseo et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Candida auris candidaemia in an intensive care unit - Prospective observational study to evaluate epidemiology, risk factors, and outcome
Prakash S. Shastri et al.
JOURNAL OF CRITICAL CARE (2020)
Nikkomycin Z-Ready to Meet the Promise?
David J. Larwood
JOURNAL OF FUNGI (2020)
Multidrug-Resistant Candida auris Infections in Critically III Coronavirus Disease Patients, India, April-July 2020
Anuradha Chowdhary et al.
EMERGING INFECTIOUS DISEASES (2020)
Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model
Lajos Forgacs et al.
EMERGING MICROBES & INFECTIONS (2020)
Antifungal activity and killing kinetics of anidulafungin, caspofungin and amphotericin B against Candida auris
Catiana Dudiuk et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Differential recognition of Candida tropicalis, Candida guilliermondii, Candida krusei, and Candida auris by human innate immune cells
Maria J. Navarro-Arias et al.
INFECTION AND DRUG RESISTANCE (2019)
Hospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016
Paige A. Armstrong et al.
EMERGING INFECTIOUS DISEASES (2019)
Persistent candidemia despite appropriate fungal therapy: First case of Candida auris from the United Arab Emirates
Adnan Alatoom et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2018)
An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital
Alba Ruiz-Gaitan et al.
MYCOSES (2018)
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Shawn R. Lockhart et al.
CLINICAL INFECTIOUS DISEASES (2017)
Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species
Andrew M. Borman et al.
MSPHERE (2016)
Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?
A. Espinel-Ingroff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology
Judit Szilagyi et al.
JOURNAL OF CHEMOTHERAPY (2012)
Pharmacokinetics of Nikkomycin Z after Single Rising Oral Doses
David E. Nix et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis
Robert F. Betts et al.
CLINICAL INFECTIOUS DISEASES (2009)
Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B
H. Sandovsky-Losica et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2007)